Niclas Högberg and William ‘Obi’ Greenman on Evolving Strategies in Massive Bleeding Management
Niclas Högberg, Sales Director at Cerus, reposted from William “Obi” Greenman on LinkedIn:
”MASSIVE BLEEDING – ARE WE DRIFTING APART IN STRATEGY?
In the U.S., 5-day Pathogen-Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) is beginning to reshape massive transfusion practice.
As the study included concluded:
- “PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.”
This evolution enables clinicians to act within minutes — moving beyond ratio-driven MTPs toward targeted, function-based hemostatic resuscitation.
Across Europe and the Nordics, focus has instead shifted toward Whole Blood (WB) for trauma and pre-hospital use.
While physiologically balanced, WB reintroduces challenges with traceability, shelf life, and pathogen safety — factors that SoHO and IVDR will soon regulate more tightly.
As Europe strengthens its blood preparedness and resilience, the key question is:
- Are we innovating forward — or reinventing the past for convenience?”
William “Obi” Greenman, Chairman and Chief Executive Officer at Cerus, shared on LinkedIn:
”The expansion of INTERCEPT Fibrinogen Complex use in large U.S. hospitals is really encouraging given the meaningful impact on immediate fibrinogen delivery in critically bleeding patients.
With >50% improvements in delivery time and reduced wastage, the efficiencies gained are real and the hospital transfusion service teams love the product and can focus their valuable time on other critical activities.”
Read the full article here.
Article: Pathogen-reduced cryoprecipitate: Early experiences and inventory management
Authors: C. B. Webb, A. Javanbakht, D. Hanna, S. G. Yates, R. Zhang, S. Afraz, R. Sarode
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 4, 2025, 10:26Gaetan Duport about HTA and Reimbursement Models in Treatments for Bleeding Disorders
-
Oct 3, 2025, 16:31Ronit Kar and Team Used Microfluidic Technology and Found That Platelets From Pediatric Trauma
-
Oct 3, 2025, 07:53Pancytopenia in Pregnancy: A Time-Critical Hematological Emergency
-
Oct 2, 2025, 14:12Helen McPherson at ISFP-IFRS 2025: Fibrin Clot Structure and Function Modulation by Targeting Fibrinogen aC Region
-
Oct 2, 2025, 10:48Kanishk Kumar: TFPI Market Size - Advancing Hemostasis and Antithrombotic Therapy
-
Oct 4, 2025, 10:23Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman's Latest Analysis on Emicizumab
-
Oct 4, 2025, 10:19Alexandre Kauskot Thanks Marie A Hollenhorst on Her Editorial On His Recent Publication on Platelet Glycotime
-
Oct 4, 2025, 10:10Alessio Branchini Shares His Latest Work on Albumin-Fused Factor IX Variants and Thanks The Whole Team
-
Oct 3, 2025, 16:37Steven Murphy Highlights New Research Linking POTS Platelets to Storage Pool Deficiency
-
Oct 3, 2025, 16:33Roberta Gualtierotti and Jacopo Acquati Lozej Will Explore Strategies to Preserve Joint Health
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 4, 2025, 10:21Maria Elisa Mancuso: Chance to Listen to Inspiring Experiences of People Who Live With Bleeding Disorders
-
Oct 4, 2025, 10:04Stéphanie Roullet Gave Talk on Platelet-Inspired Nanoparticles at SFTH 2025 Congress
-
Oct 4, 2025, 09:55NBDF: Proud to See Our Own Teri F Willey Representing the Foundation in the Funding Rare Disease Research Webinar
-
Oct 4, 2025, 09:49Emmanuel J Favaloro: Promoting World Thrombosis Day Whilst Giving a Talk in Tasmania
-
Oct 3, 2025, 14:48Maha Othman - Elected as the Co-Lead for the Basic and Translational Research Platform at CanVECTOR Research Network